1. Signaling Pathways
  2. GPCR/G Protein
  3. Platelet-activating Factor Receptor (PAFR)
  4. Platelet-activating Factor Receptor (PAFR) Antagonist

Platelet-activating Factor Receptor (PAFR) Antagonist

Platelet-activating Factor Receptor (PAFR) Antagonists (11):

Cat. No. Product Name Effect Purity
  • HY-N0784
    Ginkgolide B
    Antagonist 99.96%
    Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.
  • HY-132190
    Hexanolamino PAF C-16
    Antagonist
    Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca2+-dependent and -independent pathways. Related to platelet aggregation.
  • HY-116120
    N-Acetyldesloratadine
    Antagonist
    N-Acetyldesloratadine (SCH-37370) is a potent, orally active dual antagonist of platelet-activating factor (PAF) and histamine. N-Acetyldesloratadine inhibits PAF-induced aggregation of human platelets, with an IC50 of 0.6 µM.
  • HY-N3436
    Kadsurin A
    Antagonist
    Kadsurin A is a new lignan can be isolated from Piper futokadsura. Kadsurin A is a platelet activating factor (PAF) receptor antagonist that weakly inhibits the binding of PAF to its receptor.
  • HY-121377
    Epiyangambin
    Antagonist
    Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells).
  • HY-N10663
    Kadsurenone
    Antagonist ≥99.0%
  • HY-106837
    Israpafant
    Antagonist
    Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC50s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca2+ influx and intracellular Ca2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice.
  • HY-106833A
    SDZ-62-434
    Antagonist
    SDZ-62-434 is a platelet-activating factor (PAF) antagonist. SDZ-62-434 has antiproliferative activity in human solid and haematological malignancies.
  • HY-123399
    Ro 19-1400
    Antagonist
    Ro 19-1400 is a platelet-activating factor antagonist that directly inhibits immunoglobulin E-dependent mediator release.
  • HY-N7343
    Pregomisin
    Antagonist
    Pregomisin is a natural compound isolated from the fruits of Schizandra chinensis Baill. Pregomisin showed PAF antagonistic activity and the IC50 values were 48 μM.
  • HY-N11920
    Kadsurenin B
    Antagonist
    Kadsurenin B is a PAF (platelet-activating factor) antagonist with neuroprotective activity. Kadsurenin B has a wide range of pharmacological research potential, such as antibacterial, anti-inflammatory, neuroprotective, antioxidant, antiplatelet aggregation, cytotoxic, antiparasitic, etc.